siponimod (Mayzent)
Jump to navigation
Jump to search
Indications
- treatment of adults with relapsing forms of multiple sclerosis, including active secondary progressive multiple sclerosis[1]
Contraindications
Dosage
- oral
Monitor
- prior to initiation of therapy
- blood pressure during treatment
Adverse effects
- most common
- headache
- hypertension
- abnormal liver function tests
- other
- risk of infections
- macular edema
- decline in lung function
- transient bradycardia
- posterior reversible encephalopathy syndrome
Notes
- must be dispensed with a patient Medication Guide that describes important information about uses & risks
- FDA approval granted to Novartis March 2019
More general terms
References
- ↑ 1.0 1.1 FDA News Release. March 26, 2019 FDA approves new oral drug to treat multiple sclerosis. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm634469.htm